AI Summary
We reviewed 86 live results for biosimilar and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Monoclonal Antibodies.
Comparison Table
Recommended
Bevacizumab Biosimilar
Source: Biocon Biologics Philippines Inc.
Description
An oncology biosimilar used in the treatment of various solid tumors, expanding therapeutic options for cancer patients.
Best for
solid tumor treatment, cancer therapy and oncology clinics
Tags
View Details
Rating
Trastuzumab Biosimilar
Source: Biocon Biologics Philippines Inc.
Description
A biosimilar monoclonal antibody for the treatment of HER2-positive breast and gastric cancers, available in the Philippines since 2018.
Best for
HER2-positive breast cancer, gastric cancer treatment and oncology therapy
View Details
Rating
Steqeyma (ustekinumab biosimilar)
Source: Celltrion Healthcare
Description
Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL).
Best for
subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users
View Details
Rating
| Compare | Bevacizumab Biosimilar | Trastuzumab Biosimilar | Steqeyma (ustekinumab biosimilar) |
|---|---|---|---|
| Source | Biocon Biologics Philippines Inc. | Biocon Biologics Philippines Inc. | Celltrion Healthcare |
| Description | An oncology biosimilar used in the treatment of various solid tumors, expanding therapeutic options for cancer patients. | A biosimilar monoclonal antibody for the treatment of HER2-positive breast and gastric cancers, available in the Philippines since 2018. | Steqeyma is a biosimilar version of ustekinumab that has received approval from the Singapore Health Sciences Authority (HSA). It is indicated for treating inflammatory conditions such as plaque psoriasis and Crohn's disease, and is slated for subsidy under the Ministry of Health's Standard Drug List (SDL). |
| Best for | solid tumor treatment, cancer therapy and oncology clinics | HER2-positive breast cancer, gastric cancer treatment and oncology therapy | subsidized drug seekers in Singapore, long-term inflammatory care and HSA-approved biosimilar users |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Bevacizumab Biosimilar from Biocon Biologics Philippines Inc.."
I picked this because It serves as an essential biosimilar for treating diverse solid tumor types in cancer care.
Share this search
Related Finds